Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Corona, California-based manufacturer of beverages, Hansen Natural Corporation ( ) in a bid to enhance shareholders’ value and retain their long-term confidence in the company recently announced a share repurchase program. As per the announcement, the company will repurchase common shares worth $250 million.
Hansen stated that currently it has no shares outstanding for repurchase as the company has completed its previously announced share buyback program worth $200 million. As of June 30, 2011, Hansen had about 93.6 million shares outstanding.
Hansen remains committed to enhancing shareholders’ value by returning capital through share repurchases. These strategies will bolster shareholders' return and raise the market value of the stock.
Further, Hansen possesses strong liquidity to support the share buyback program. At the end of the second quarter, the company had cash and cash equivalents of $418.2 million.
In the recently concluded quarter, Hansen posted earnings per share of 90 cents comprehensively beating the Zacks Consensus Estimate of 83 cents and the year-ago quarter earnings of 69 cents. The better-than-expected results were driven by double-digit top-line growth.
Hansen’s gross sales surged 27.0% year over year in the second quarter to $527.5 million and net sales jumped 26.4% to $462.1 million. Gross margin slipped by 10 basis points to 52.8% due to higher cost of sales. However, operating income for the quarter rose 20.8% to $132.5 million.
Currently, we maintain our long-term Outperform recommendation on the stock. Moreover, Hansen holds a Zacks #1 Rank, which translates into a short-term ‘Strong Buy’ rating. Hansen's peers include Pepsico, Inc. ( PEP - Analyst Report ) and National Beverage Corp. ( FIZZ ) .
Read the full Analyst Report on PEP
Read the full on FIZZ